134 related articles for article (PubMed ID: 36507652)
1. Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure.
Alarcan H; Cannet P; Camus V; Fond G; Zendjidjian X; Guilhaumou R; Quaranta S
Br J Clin Pharmacol; 2023 May; 89(5):1665-1671. PubMed ID: 36507652
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.
Ghotbi R; Christensen M; Roh HK; Ingelman-Sundberg M; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2007 Jun; 63(6):537-46. PubMed ID: 17370067
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 1A2 activity and incidence of thyroid disease and cancer after chronic or acute exposure to dioxins.
Samer CF; Gloor Y; Rollason V; Guessous I; Doffey-Lazeyras F; Saurat JH; Sorg O; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):296-303. PubMed ID: 31608602
[TBL] [Abstract][Full Text] [Related]
5. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population.
Gunes A; Ozbey G; Vural EH; Uluoglu C; Scordo MG; Zengil H; Dahl ML
Pharmacogenomics; 2009 May; 10(5):769-78. PubMed ID: 19450128
[TBL] [Abstract][Full Text] [Related]
6. Use of caffeine as a probe for rapid determination of cytochrome P-450 CYP1A2 activity in humans.
Ou-Yang DS; Huang SL; Xie HG; Wang CY; Zhou HH
Zhongguo Yao Li Xue Bao; 1998 Jan; 19(1):44-6. PubMed ID: 10375757
[TBL] [Abstract][Full Text] [Related]
7. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2.
Han XM; Ou-Yang DS; Lu PX; Jiang CH; Shu Y; Chen XP; Tan ZR; Zhou HH
Pharmacogenetics; 2001 Jul; 11(5):429-35. PubMed ID: 11470995
[TBL] [Abstract][Full Text] [Related]
8. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers.
Wang L; Hu Z; Deng X; Wang Y; Zhang Z; Cheng ZN
Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):257-63. PubMed ID: 23167834
[TBL] [Abstract][Full Text] [Related]
9. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
10. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity.
Sinués B; Fanlo A; Bernal ML; Mayayo E; Soriano MA; Martínez-Ballarin E
Ther Drug Monit; 2002 Dec; 24(6):715-21. PubMed ID: 12451287
[TBL] [Abstract][Full Text] [Related]
11. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.
Welfare MR; Aitkin M; Bassendine MF; Daly AK
Pharmacogenetics; 1999 Jun; 9(3):367-75. PubMed ID: 10471069
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.
Muscat JE; Pittman B; Kleinman W; Lazarus P; Stellman SD; Richie JP
Biochem Pharmacol; 2008 Oct; 76(7):929-37. PubMed ID: 18703023
[TBL] [Abstract][Full Text] [Related]
13. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.
Welfare MR; Bassendine MF; Daly AK
Br J Clin Pharmacol; 2000 Mar; 49(3):240-3. PubMed ID: 10718779
[TBL] [Abstract][Full Text] [Related]
14. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
15. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Czerwensky F; Leucht S; Steimer W
Ther Drug Monit; 2015 Apr; 37(2):152-60. PubMed ID: 25090458
[TBL] [Abstract][Full Text] [Related]
16. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
Hakooz NM
Curr Drug Metab; 2009 May; 10(4):329-38. PubMed ID: 19519341
[TBL] [Abstract][Full Text] [Related]
17. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.
Eap CB; Bender S; Jaquenoud Sirot E; Cucchia G; Jonzier-Perey M; Baumann P; Allorge D; Broly F
J Clin Psychopharmacol; 2004 Apr; 24(2):214-9. PubMed ID: 15206669
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
[TBL] [Abstract][Full Text] [Related]
19. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes.
Djordjevic N; Ghotbi R; Bertilsson L; Jankovic S; Aklillu E
Eur J Clin Pharmacol; 2008 Apr; 64(4):381-5. PubMed ID: 18157525
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
